1236265-93-2

Basic information

• Product Name: 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide
• Synonyms: 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide
• CAS NO: 1236265-93-2
• Molecular Weight: 436.944
• Mol File: 1236265-93-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide(1236265-93-2)
• EPA Substance Registry System: 4-((4-chloro-6-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide(1236265-93-2)

Safety Data

• Hazardous Substances Data: 1236265-93-2(Hazardous Substances Data)

Upstream product

• 33233-67-9 4-(tert-Butoxycarbonylaminomethyl)benzoic acid 
• 14099-81-1 1,2,3,4-tetrahydroisoquinoline 
• 884195-75-9 2-(4,6-dichloro[1,3,5]triazin-2-yl)-1,2,3,4-tetrahydroisoquinoline 
• 1236265-91-0 4-(aminomethyl)-N-ethyl-N-methylbenzamide TFA salt 

Downstream Products

• 1236265-27-2 4-((4-(3,4-dihydroisoquinolin-2(1H)-yl)-6-(ethyl(methyl)amino)-1,3,5-triazin-2-ylamino)methyl)-N-ethyl-N-methylbenzamide 
• 1236265-22-7 4-((4-(3,4-dihydroisoquinolin-2(1H)-yl)-1,3,5-triazin-2-ylamino)methyl)-Nethyl-N-methylbenzamide 

Relevant articles and documents

Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT)

The aggrecan degrading metalloprotease ADAMTS-4 has been identified as a novel therapeutic target for osteoarthritis. Here, we use DNA-encoded Library Technology (ELT) to identify novel ADAMTS-4 inhibitors from a DNA-encoded triazine library by affinity selection. Structure-activity relationship studies based on the selection information led to the identification of potent and highly selective inhibitors. For example, 4-(((4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-6-(((4-methylpiperazin-1-yl)methyl)amino)-1,3,5-triazin-2-yl)amino)methyl)-N-ethyl-N-(m-tolyl)benzamide has IC50 of 10 nM against ADAMTS-4, with >1000-fold selectivity over ADAMT-5, MMP-13, TACE, and ADAMTS-13. These inhibitors have no obvious zinc ligand functionality.